Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | RARB | P10826 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482659 | 0.96 | TP53 (0.69) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL8092356 | 0.95 | RARB (0.67) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL5477923 | 0.94 | TP53 (0.72) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL303140 | 0.94 | TP53 (0.72) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL303109 | 0.94 | TP53 (0.72) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL5096607 | 0.94 | TP53 (0.72) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL4743266 | 0.94 | TP53 (0.72) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL9666009 | 0.94 | TP53 (0.72) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL2592329 | 0.90 | PKM (0.69) | PKMTSHRTP53PLA2G4BALDH1A1 | |
| SCHEMBL9630999 | 0.90 | RARB (0.74) | PKMTSHRTP53PLA2G4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2026-03-24 | — | — | US | disclosed |
| CN-114981241-B | Novel compounds, process for their preparation and their use | 大邱庆北尖端医疗产业振兴财团 | 2024-11-19 | — | — | CN | disclosed |
| CN-116987061-A | 4-methyl quinazoline derivative, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-11-03 | — | — | CN | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | PIMEDBIO, INC. (KR) | 2023-05-11 | — | — | US | disclosed |
| EP-4065553-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | Daegu-Gyeongbuk Medical Innovation Foundation (KR) | 2022-10-05 | — | — | EP | disclosed |
| CN-114981241-A | Novel compound, preparation method and application thereof | 大邱庆北尖端医疗产业振兴财团 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021145729-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-07-22 | — | — | WO | disclosed |
| EP-1948664-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-28 | — | — | US | disclosed |
| WO-2007061882-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007061882-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1083888-A1 | MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999063983-A9 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999063983-A1 | MULTIBINDING AGENTS THAT MODULATE PPARη AND RXR RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-4461905-A | THROMBOXANE SYNTHETASE INHIBITOR INTERMEDIATE | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583818-B2 | Compound, preparation method thereof, and use thereof | TYRO3, TH, SRMS | PKM 4091/4885TSHR 565/4885TP53 4089/4885 |
| US-20230142654-A1 | NOVEL COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF | TYR, TYRO3, TH | PKM 1222/4885TSHR 3654/4885TP53 3755/4885 |
| US-20070149534-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK3, NTRK1 | PKM 1210/4885TSHR 414/4885TP53 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.